Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Idiopathic Inflammatory Myopathies Clinical Trials

11 recruiting trials for Idiopathic Inflammatory Myopathies. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
11
Total Trials
11
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Recruiting Trials

RECRUITINGPhase 1NCT07295847

A Study of AZD0120 in Autoimmune Diseases

This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult...

Sponsor: AstraZenecaEnrolling: 2718 locations
RECRUITINGNCT06361745

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Main purpose: To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID). Secondary purpose: To evaluate the...

Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.Enrolling: 101 location
RECRUITINGPhase 1 / Phase 2NCT06733935

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019...

Sponsor: Nkarta, Inc.Enrolling: 14415 locations
RECRUITINGPhase 1 / Phase 2NCT06350110

Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)

This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002...

Sponsor: Essen BiotechEnrolling: 751 location
RECRUITINGPhase 1NCT06316076

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

To evaluate the safety and efficacy of CD19-CAR-DNT cells in subjects with relapsed/refractory autoimmune diseases

Sponsor: RenJi HospitalEnrolling: 481 location
RECRUITINGPhase 1 / Phase 2NCT07022197

Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

This study is a phase Ib/IIa dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous T cells expressing chimeric antigen...

Sponsor: Tianjin Medical University General HospitalEnrolling: 271 location
RECRUITINGEarly Phase 1NCT04561557

Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous...

Antibody-mediated inflammatory diseases of the nervous system (also known as autoimmune diseases of the nervous system) are autoimmune diseases in which autoimmune cells and...

Sponsor: Tongji HospitalEnrolling: 361 location
RECRUITINGNCT06502015

Biomarkers in Autoimmune Disease of Nervous System

Neurological autoimmune diseases are a group of disorders characterized by the abnormal immune response attacking the nervous system, including the brain, spinal cord and...

Sponsor: Tongji HospitalEnrolling: 500001 location
RECRUITINGNCT04664465

PRediction of DIverse Glucocorticoids ToxIcity OUtcomeS

To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid...

Sponsor: University Hospital, BrestEnrolling: 30011 locations
RECRUITINGNCT06696027

AYLo - AutoimmunitY and Loss of y

The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims...

Sponsor: University of BonnEnrolling: 5001 location
RECRUITINGPhase 2NCT06285539

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) is limited due to small patient populations. Patients with Behçet's disease (BD), idiopathic...

Sponsor: UMC UtrechtEnrolling: 606 locations